Lexicon Pharmaceuticals Inc Stock Price, News & Analysis

Lexicon Pharmaceuticals announced topline results from the RELIEF-PHN-1 Phase 2 study of LX9211 for postherpetic neuralgia, demonstrating a reduction of 2.42 in average daily pain score (ADPS) at week 6 compared to a 1.62 reduction in the placebo group. Though not statistically significant at the primary endpoint (p=0.12), a consistent effect was noted across the dosing period (p=0.03). The adverse event profile was similar to prior studies, with dizziness being the most common issue. A full analysis will be shared at a medical conference.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will participate in two investor conferences on November 29 and December 1, 2022. The conferences include the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference. Key executives, including CEO Lonnel Coats and CFO Jeffrey Wade, will engage in discussions at these events. Webcasts of the discussions will be accessible on Lexicon's website, with recordings available for two weeks post-event. Lexicon focuses on developing innovative medicines targeting various diseases.

Lexicon Pharmaceuticals (LXRX) announced successful results from the RELIEF-DPN-1 trial of its investigational drug LX9211, aimed at treating diabetic peripheral neuropathic pain. The trial achieved its primary endpoint, showing a statistically significant reduction in average daily pain score (ADPS) at week 6. Significant benefits were also noted in reducing burning pain and sleep interference. No withdrawal symptoms or rebound pain were observed post-treatment. The company plans to advance LX9211 to phase 3 development in 2023, further supporting its potential as a treatment for neuropathic pain.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced its participation in the 13th Annual Jefferies London Healthcare Conference from November 15-17, 2022. Jeff Wade, the company's president and CFO, is set to present, with the on-demand presentation available starting 7:55 am ET on November 16. The webcast will be accessible in the Events section of Lexicon's website, with a recording available for two weeks post-event.

Lexicon focuses on pioneering medicines for various diseases through its Genome5000™ program.

Lexicon Pharmaceuticals (LXRX) announced its financial results for Q3 2022, reporting a net loss of $23.4 million, or $0.13 per share. The FDA's review of their NDA for sotagliflozin for heart failure is on track for a PDUFA date in May 2023. The company presented new data from the SOLOIST-WHF trial highlighting sotagliflozin's benefits in reducing cardiovascular mortality. Additionally, final results from the RELIEF-DPN-1 study of LX9211 in painful diabetic neuropathy will be presented at an upcoming summit. As of September 30, 2022, Lexicon had $136.2 million in cash and investments.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the final results from its Phase 2 RELIEF-DPN-1 trial for LX9211, a selective AAK1 inhibitor, aimed at treating diabetic peripheral neuropathic pain. The results will be presented on November 14, 2022, showing a significant reduction in pain scores compared to placebo. The study enrolled 319 patients across 45 clinical sites, demonstrating potential efficacy and safety. The company also plans to release results from another related study by year-end 2022.

Lexicon Pharmaceuticals announced significant findings from the SOLOIST-WHF Phase 3 study at the American Heart Association Scientific Sessions 2022, showing that sotagliflozin reduced the risk of hospital readmissions for heart failure by 46% to 52% within 30 to 90 days post-discharge compared to placebo. Heart failure leads to approximately 1 million hospitalizations annually in the U.S., costing nearly $70 billion by 2030. The results suggest that sotagliflozin could alleviate burdens on patients and the healthcare system.

Lexicon Pharmaceuticals (Nasdaq: LXRX) presented a post hoc analysis from the SCORED trial on sotagliflozin at the American Society of Nephrology Kidney Week 2022. The analysis demonstrates significant reductions in the urine albumin-to-creatinine ratio (UACR), achieving a 26% reduction in kidney disease progression risk and a 34% increase in regression to lower UACR categories. This data highlights the potential benefits of sotagliflozin for patients with type 2 diabetes and chronic kidney disease, reinforcing its therapeutic promise in managing kidney risks.

Lexicon Pharmaceuticals (Nasdaq: LXRX) will announce its third quarter 2022 financial results on November 9, 2022, after market close. A conference call will follow at 5:00 p.m. ET to discuss results and provide business updates. Interested parties can access the call at the provided dial-in numbers and listen to a replay for 14 days. Lexicon focuses on pioneering innovative medicines through its Genome5000™ program, targeting significant therapeutic proteins across various diseases, with ongoing development in heart failure, diabetes, and more.